Alpha Paradigm Partners, LLC Veracyte, Inc. Transaction History

Alpha Paradigm Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$16.58 - $27.9 $1.36 Million - $2.28 Million	81,733 Added 165.68%	131,064 $2.18 Million
Q2 2022 Aug 15, 2022	BUY	$15.45 - $29.52 $159,026 - $303,849	10,293 Added 26.37%	49,331 $982 Million
Q1 2022 May 16, 2022	SELL	$21.94 - $42.51 $27,446 - $53,180	-1,251 Reduced 3.11%	39,038 $1.08 Billion
Q4 2021 Feb 14, 2022	BUY	$36.09 - $53.79 $1.45 Million - $2.17 Million	40,289 New	40,289 $1.66 Billion
Q3 2021 Nov 15, 2021	SELL	$35.62 - $52.97 $2.58 Million - $3.83 Million	-72,342 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$32.94 - $56.62 $2.38 Million - $4.1 Million	72,342 New	72,342 $2.89 Billion

307

81.6M

134K

13.3K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.97B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Alpha Paradigm Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Paradigm Partners, LLC with notifications on news.